Stage I/II Nasal NK Cell Lymphoma

Phase 1 & 2

Waitlist Available

Led By Bouthaina Dabaja, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 to disease progression or death (up to 5+ years)

Awards & highlights

No Placebo-Only Group

All Individual Drugs Already Approved

Approved for 30 Other Conditions

Summary

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control stage 1 and/or 2 NK cell lymphoma. The safety of radiation and chemotherapy will also be studied.

Eligible Conditions

Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1 to disease progression or death (up to 5+ years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1 to disease progression or death (up to 5+ years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to disease progression or death (up to 5+ years) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Progression-free Survival (PFS)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Approved for 30 Other Conditions

This treatment demonstrated efficacy for 30 other conditions.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Radiation + ChemotherapyExperimental Treatment5 Interventions

Radiation therapy total dose of 50.4 to 54 Gy over 28 to 30 treatments; CHOP Chemotherapy of Cyclophosphamide 750 mg/m2 intravenous piggyback (IVPB), Doxorubicin 50 mg/m2 IVPB, Vincristine 1.4 mg/m2 (max dose 2 mg) IVPB on Day 1, and Oral Prednisone 100 mg daily days 1-5 for four 21-day cycles.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Vincristine

FDA approved

Prednisone

FDA approved

Doxorubicin

FDA approved

Radiation

2003